KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). While α-MSH itself is a 13-amino acid peptide with widespread effects including skin pigmentation and appetite regulation, the KPV sequence has been identified as the minimum active fragment responsible for most of α-MSH's potent anti-inflammatory activity.
Origin: From α-MSH to KPV
Alpha-MSH (α-melanocyte-stimulating hormone) is a neuropeptide processed from POMC (pro-opiomelanocortin). It binds melanocortin receptors (MC1R-MC5R) and has long been known for its role in skin pigmentation (MC1R) and appetite suppression (MC4R).
However, research by Catania and colleagues in the 1990s-2000s demonstrated that many of α-MSH's anti-inflammatory effects could be reproduced by its C-terminal tripeptide KPV — and that KPV retained these effects without the pigmentation and appetite-related activity of the full molecule.
This selectivity makes KPV an ideal research tool for studying anti-inflammatory mechanisms in isolation.
Mechanism of Action
NF-κB Inhibition: KPV's primary anti-inflammatory mechanism is inhibition of NF-κB signaling — the master transcription factor for pro-inflammatory gene expression. By reducing NF-κB nuclear translocation, KPV decreases production of TNF-α, IL-1β, IL-6, and IL-8.
Direct Cell Penetration: A distinctive feature of KPV is its ability to penetrate cells directly, without receptor binding — allowing it to act intracellularly on NF-κB and related pathways.
Macrophage Modulation: KPV shifts macrophage polarization away from the M1 (pro-inflammatory) phenotype. In inflamed tissue models, KPV-treated macrophages show reduced expression of iNOS and COX-2 and increased expression of anti-inflammatory markers.
Epithelial Barrier Function: In gut epithelial cultures, KPV has been shown to enhance tight junction protein expression (ZO-1, occludin, claudins) — strengthening the mucosal barrier that breaks down in IBD.
Inflammatory Bowel Disease Research
The most studied application of KPV is inflammatory bowel disease. In DSS-induced colitis models (a standard mouse model of ulcerative colitis), KPV has consistently shown:
- Reduced colon shortening (a marker of inflammation severity)
- Lower disease activity index scores
- Histological improvement in mucosal architecture
- Reduced pro-inflammatory cytokines in colon tissue
- Enhanced epithelial barrier function
Oral administration has been examined, with some evidence that KPV can reach the colon intact — particularly when formulated in hydrogel or nanoparticle delivery systems that protect it from gastric degradation.
Skin and Wound Research
KPV's anti-inflammatory and cell-penetrating properties have also been studied in skin contexts:
- Topical KPV has shown efficacy in models of contact dermatitis and psoriasis-like inflammation
- It promotes wound closure in excisional wound models, likely through combined anti-inflammatory and cell migration effects
- Formulated in hydrogel, it has shown sustained local anti-inflammatory activity without systemic exposure
This localized activity profile is attractive for skin research where systemic immunosuppression is not desired.
Published References
Research Use Only. All content is for informational and educational purposes regarding preclinical research. None of the compounds discussed have been approved by the FDA for human therapeutic use. This information does not constitute medical advice.
TB-500 & Thymosin Beta-4 Research
9 min readTestosterone Cypionate: Research Overview
11 min read